ENVALITH

WIN-Partners Co., Ltd. 2Q Earnings Call Flash

Record 1H Profits on PFA and Medical Equipment; Management Calls Full-Year Plan Conservative, Targeting JPY 100B in Revenue and First Record Profit in Eight Years

PublishedNovember 18, 2026 at 18:11 GMT+9

Summary

In 2Q FY3/27, revenue rose across all product categories. Revenue and profit at every level hit record highs for a first half and beat the initial plan. In CRS, growth was driven by PFA devices and leadless pacemakers. Medical equipment expanded on completion of large-scale installation projects that had slipped from the prior quarter. A higher mix of medical equipment lifted the gross profit margin. The full-year plan was left unchanged. Management said the planned 2H profit decline reflects a conservative stance rather than any specific negative factors.

Key Points

  • Management Strategy and Market View
    • The June medical fee revision was the largest increase in 30 years. Customer interviews suggest earnings at regional core hospitals are improving.
    • Rising labor costs from staff shortages and broader inflation show no sign of easing soon. Management sees the operating environment for medical institutions as far from comfortable.
    • As healthcare DX expands, cybersecurity preparedness has become essential. The company has made digital-led business expansion a core pillar of its growth strategy.
  • Business Progress and Drivers
    • Medical equipment benefited from completion of large-scale projects delayed from 1Q and from 2Q deliveries. Including unplanned projects, the category beat plan by JPY 952M.
    • CRS beat plan by JPY 715M on growth in PFA devices and leadless pacemakers. CVS benefited from more facilities performing stent graft procedures.
    • PCI missed plan by JPY 205M due to slower new customer acquisition. It was the only major consumables category to fall short of plan.
    • Expenses rose 16.2%, driven by costs related to the Plasten Medical acquisition and higher depreciation. However, both personnel costs and other expenses came in below plan, contributing to the operating income beat.
  • Key Strategic Initiatives and Changes
    • Following the Kanto-area offices, logistics for facilities served by the Yokohama sales office are now being transferred to WIN Heart Gate. The separation of commercial and logistics functions is on schedule.
    • WIN Asset, launched in April, has been well received by adopting facilities and is generating strong inquiry levels. The company aims to secure earnings by leading equipment procurement planning and price negotiations with manufacturers.
    • Shinzo-kun has added cloud connectivity and AI functions, supporting more efficient hospital operations and fewer missed insurance claims.
    • Supplier price increase requests are being handled through price negotiations coordinated with customers. Backed by higher gross profit, the company has also strengthened its rebate program.

Outlook

  • The full-year plan is unchanged at revenue of JPY 100,000M (+10.6%) and operating income of JPY 3,350M (+10.9%). The company aims to cross the JPY 100B revenue mark and post its first record profit in eight years.
  • 1H operating income progress stands at 61.6% (our estimate). The plan implies a 17.3% YoY decline in 2H profit (our estimate), but management describes its assumptions as conservative.
  • In CRS, a new manufacturer plans to launch a dual-use device for both PFA and ablation, which is expected to energize the market. In PPI, management also expects higher use of renal denervation devices.
  • The plan assumes a gross profit margin of 12.0% (+0.2pp). SG&A is set to rise to JPY 8.61B (+12.7%), which the company intends to absorb through revenue growth and margin expansion.
  • The hiring environment remains tight, but the company is focusing on mid-career recruitment and plans a year-end headcount of 729.
  • The year-end dividend is planned at JPY 55, up JPY 1 (forecast payout ratio of 68.4%). Capex is planned at JPY 430M.

Positive Factors

  • Gross profit margin rose YoY despite reimbursement price revisions, helped by a higher mix of more profitable medical equipment.
  • The June 2026 revision left reimbursement prices unchanged for PFA, DCB, TAVI bioprosthetic valves and stent grafts, preserving unit prices for growth products.
  • Volume rose 11.1% in PPI and 7.1% in CRS. Value growth outpaced volume in both, pointing to a mix shift toward higher-priced products.
  • SG&A grew more slowly than revenue, confirming a structure in which top-line growth flows through readily to profit.
  • Non-operating income increased to JPY 41M (JPY 31M a year earlier), driven by higher interest income on investment securities as rates rose.

Concerns

  • Operating cash flow shrank to JPY 22M (JPY 1,702M a year earlier). The main drivers were a JPY 2,588M increase in trade receivables and higher inventories.
  • Cash and cash equivalents stood at JPY 9,267M (JPY 10,931M at the start of the period). With working capital rising alongside a high payout ratio, cash on hand continues to decline.
  • The June reimbursement price revision is expected to reduce revenue by 1.2% overall (company estimate), and by 1.6% in PCI. For PCI, this compounds the shortfall against plan.
  • Supplier price increase requests and rising personnel costs persist. Margins will hinge on the company's ability to pass through costs and secure hires.
  • Medical equipment results are sensitive to project timing slippage. The Other category was 35.2% below plan in 1H, yet the full-year plan calls for +71.0%, requiring a strong buildup in 2H.
  • Cyber risk is rising as healthcare DX expands. Any attack on a customer hospital could disrupt the company's operations.

Performance Highlights

For 1H cumulative, revenue was JPY 51,600M (+18.0%), operating income JPY 2,065M (+40.9%) and net income JPY 1,398M (+38.1%), marking higher revenue and profit. All exceeded plan, with revenue +3.4%, operating income +20.8% and net income +22.7% versus plan.

Segment Performance

SegmentRevenueYoYOperating IncomeYoY
Cardiac Rhythm Management (CRS)JPY 13,875M+11.7%――
Ischemic Heart Disease (PCI)JPY 10,444M+7.5%――
Cardiovascular Surgery (CVS)JPY 8,212M+8.8%――
Medical EquipmentJPY 7,232M+91.1%――
Diabetes (DMS)JPY 3,109M+11.9%――
Peripheral Vascular Disease (PPI)JPY 2,979M+21.0%――
NeurosurgeryJPY 2,349M+15.2%――
NON-BusJPY 2,080M+11.8%――
OtherJPY 1,316M+17.0%――
  • Gross Profit: JPY 6,117M (+19.0% YoY, our estimate)
  • Gross Profit Margin: 11.9% (+0.1pt YoY)
  • Operating Income Margin: 4.0% (3.4% a year earlier)
  • SG&A: JPY 4,052M (+10.3% YoY)
  • Recurring Profit: JPY 2,104M (+41.7% YoY)
  • Group Headcount: 676 (+30 YoY)
  • EPS: JPY 50.87 (JPY 36.11 a year earlier)

Q&A List

  • Q

    A

    No Q&A session was held at this briefing.

Disclaimer

ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.

  • Purpose and Disclaimer Regarding Investment Decisions

    This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.

  • Information Sources, Accuracy, and Disclaimer of Warranty

    This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.

  • Limitation of Liability

    ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.

  • Potential Conflicts of Interest

    ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.

  • No Obligation to Change or Update Content

    The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.

  • Governing Language

    This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.

  • Copyright

    All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.

  • Use for Other Investment Products

    Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.